- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint about promotion of Fostair. PMCPA recorded no breach because the matter was outwith the scope of the Code. Undertaking received.
Alexion UK employees ‘liked’ a US LinkedIn post linking to a press release about ALXN1210. The Panel said ‘liking’ proactively disseminated it…
Complaint alleged Sanofi-sponsored meeting adverts on Facebook/Twitter lacked sponsorship statements and reached the public. Sanofi said it did not sponsor the meetings;…
PMCPA case AUTH/2909/11/16 (Director v Astellas UK) concerning clinical trial disclosure for Xtandi. Outcome: no breach; matter found outwith the scope of…
PMCPA found Ilumetri website headline claims on dosing, efficacy and QoL misleading/unsupported (Clauses 7.2, 7.4) and ruled high standards/digital requirements breached (9.1,…
Complaint alleged Novo Nordisk regional medical advisors acted promotionally and pressured reps to secure meetings/targets. Panel found complainant provided insufficient evidence; no…
Anonymous UK health professional complained Avamys banner ad on Pulse had an illegible generic name. Panel found breaches of Clauses 4.3 and…
Takeda materials for Prostap hosted on Guidelines in Practice were ruled unclear about which formulation was licensed for ovarian function preservation. Breaches…
A UK health professional challenged an Octasa 1600mg journal ad for “Always once-daily” and imagery suggesting under-18 use. The PMCPA Panel found…
A Cortiment rotating banner used the strapline “For flaring mild to moderate UC patients”, which the Panel said implied use in all…
A third-party publisher posted standalone Toctino prescribing information without GSK’s knowledge and left it live for over two years, resulting in out-of-date…
A Europe-led Lixiana email/video campaign ran without UK certification. Panel found missing AE reporting statement/date, incomplete PI (no UK cost), unsubstantiated ‘proven/ideal’…
Cosopt wrap-around on The Ophthalmologist was visible through transparent packaging and printed without the non-proprietary name. No breach for “overleaf” PI reference…
A nurse alleged a Sanofi rep emailed Toujeo Coach webinar invites without consent and said email activity was tracked. Panel found insufficient…
Sanofi’s Toujeo DoubleStar slide deck wrongly claimed “fewer prescriptions”. PMCPA ruled the claim misleading and unsubstantiated, and found inadequate rep briefing. No…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.